Translator Disclaimer
24 June 1993 Laser sclerectomy and 5-FU controlled-drug-release biodegradable implant for glaucoma therapy
Author Affiliations +
Proceedings Volume 1877, Ophthalmic Technologies III; (1993)
Event: OE/LASE'93: Optics, Electro-Optics, and Laser Applications in Scienceand Engineering, 1993, Los Angeles, CA, United States
Laser sclerectomy, a simple filtering procedure performed to alleviate high intraocular pressure in glaucoma patients, was taught to offer longer lasting effect and therefore improve the patient's outcome when compared with the standard trabeculectomy procedure. Recent clinical trials have shown that this was not the case and pharmacologic wound healing modulation is also required with this new procedure. Five-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision and positioned below the open channel. Implantation takes less than a minute. The implant releases the drug for over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure show great potentials for the treatment of glaucoma.
© (1993) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Franck L. Villain, Jean-Marie A. Parel, Katalin Kiss, Richard K. Parrish, Francois Kuhne, Yoshiko Takesue M.D., and Patrick Hostyn "Laser sclerectomy and 5-FU controlled-drug-release biodegradable implant for glaucoma therapy", Proc. SPIE 1877, Ophthalmic Technologies III, (24 June 1993);

Back to Top